N: Quote, Profile, Research) that will delay a generic version of Biovail's Cardizem LA heart drug until April 1, 2009. Biovail Laboratories International ...
The case centered on claims Biovail made regarding its two key products, Cardizem LA and Wellbutrin XL. Still, the company said the settlement "contains no ...
... about $85 million to settle a US securities class action suit that stretched back more than 4 years involving its Wellbutrin XL and Cardizem LA products.
Still, he said the deal does inject a bit of certainty into Watson's income statement and moves Cardizem LA onto investor radar screens. ...
N: Quote, Profile, Research) that will delay a generic version of Biovail's Cardizem heart drug from hitting the market until April 1, 2009. ...
Under the terms of the settlement agreement, BLS will receive a royalty based on sales of Watson's generic formulation of Biovail's Cardizem(R) LA. ...
N: Quote) that will delay a generic version of Biovail's Cardizem heart drug from hitting the market until April 2009. ACE Aviation Holdings Inc (acea. ...
Heart drug Cardizem has been the apple of discord between the two companies. The long drawn-out patent suit related to Andrx's attempt to market a generic ...
(BVF | charts | news | powerrating) on Tuesday revealed a settlement on outstanding patent litigation related to the generic version of Cardizem LA or ...
Under the terms of the settlement agreement, BLS will receive a royalty based on sales of Watson's generic formulation of Biovail's Cardizem® LA. ...